Moderna stock kpis
Want to see MRNA full AI Analyst Report?
Revenue by Segment
In Q3 2026, Moderna reported revenue by segment of $1.27B (Product Sales) and $40.00M (Grant and Collaboration).
Breaks down revenue across different business areas, revealing which segments are driving growth and how diversified Moderna's income streams are, indicating stability and strategic focus.
Product sales have shifted from pandemic-era scale to a seasonally lumpy, campaign-driven revenue stream that now hinges on respiratory launches, procurement timing and uptake; grant & collaboration income is small and immaterial to revenue volatility. Management’s reiterated growth target and recent market-share gains for mNEXSPIKE point to improving commercial traction, but near-term upside is constrained by seasonal concentration (Q3 importance), assumed non‑contribution from certain products, and a large litigation cash hit—expect uneven quarters tied to regulatory milestones and vaccine seasonality.
MRNA Revenue by Segment
| Period | Product Sales | Grant and Collaboration |
|---|---|---|
| Q3 2026Sep 30, 2026 | $1.27B | $40.00M |
| Q2 2026Jun 30, 2026 | $94.00M | $51.00M |
| Q1 2026Mar 31, 2026 | $352.00M | $37.00M |
| Q4 2025Dec 31, 2025 | $645.00M | $33.00M |
| Q3 2025Sep 30, 2025 | $973.00M | $43.00M |
| Q2 2025Jun 30, 2025 | $114.00M | $28.00M |
| Q1 2025Mar 31, 2025 | $86.00M | $22.00M |
| Q4 2024Dec 31, 2024 | $938.00M | $28.00M |
| Q3 2024Sep 30, 2024 | $1.82B | $42.00M |
| Q2 2024Jun 30, 2024 | $184.00M | $57.00M |
| Q1 2024Mar 31, 2024 | $167.00M | $0.00 |
| Q4 2023Dec 31, 2023 | $2.79B | $18.00M |
| Q3 2023Sep 30, 2023 | $1.76B | $74.00M |
| Q2 2023Jun 30, 2023 | $293.00M | $51.00M |
| Q1 2023Mar 31, 2023 | $1.83B | $34.00M |
| Q4 2022Dec 31, 2022 | $4.89B | $225.00M |
| Q3 2022Sep 30, 2022 | $3.12B | $244.00M |
| Q2 2022Jun 30, 2022 | $4.53B | $218.00M |
| Q1 2022Mar 31, 2022 | $5.92B | $141.00M |
| Q4 2021Dec 31, 2021 | $6.93B | $276.00M |
| Q3 2021Sep 30, 2021 | $4.81B | $159.00M |
| Q2 2021Jun 30, 2021 | $4.20B | $157.00M |
| Q1 2021Mar 31, 2021 | $1.73B | $204.00M |
| Q4 2020Dec 31, 2020 | $199.87M | $370.22M |
| Q3 2020Sep 30, 2020 | $0.00 | $157.91M |
| Q2 2020Jun 30, 2020 | $0.00 | $67.00M |
| Q1 2020Mar 31, 2020 | $0.00 | $8.39M |

